Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared a post on LinkedIn:
“The Milan Consensus paper on Clinical CR definition & Endpoints for next-gen bladder-sparing trials is out in JCO Journals American Society of Clinical Oncology (ASCO) | following the Ospedale San Raffaele GURetreat24.
Co-sponsored by IBCG, GSRGT
It was a tremendous multidisciplinary effort involving friends/KOL from various fields, patient advocates Bladder Cancer Advocacy Network WBCPC | Pharma Industries and FDA EMA proving insights
- cCR should be rigorously based on imaging + biopsy + urinary citology
- cCR still immature as primary endpoint for registration trials (good for esploratory studies)
- EFS good for registration trials
- EFS should capture ANY type of event including HG bladder relapses
Role of biomarkers (ctDNA/utDNA) still to conceive in this clinical setting but likely to become the next.
Read more from Andrea Necchi on OncoDaily.
